drugset / Trial / NCT04469764
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.
Timeline
- Start
- 2020-10-16
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Letrozole | Other / unclassified | — | Oral |